BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
April 30 2024 - 1:03PM
BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the
Company"), a medical technology Company delivering unprecedented
accuracy and precision to intra-cardiac signal visualization, today
announced the appointment of Mr. Anthony Amato to the Position of
Chief Executive Officer (“CEO”), effective immediately.
Additionally, Mr. Amato will serve on the Company’s Board of
Directors, which is currently being assembled. Recall, that
on April 4, 2024, the Company announced the engagement of
Consulting firm, Bridge Associates International Pharmaceutical
Consulting (“BAIPC”), led by Mr. Amato. This corporate action
was the natural progression as the Company continues to realize
meaningful progress towards its goals of both resorting and
creating lasting shareholder value.
Commenting on his appointment as CEO of BioSig, Mr. Amato
expressed, “Approximately 2 months ago, I took the initiative to
review, analyze, and address the urgent issues that had the
potential to negatively impact the Company’s future. Since then,
important and material progress has been realized on multiple
fronts, and I have accepted this new position to accelerate the
implementation of the comprehensive turnaround strategy. The
Company believes that there is substantial value to be unlocked
through its current assets including its core product line, PURE
EP™. We will continue to add the appropriate team to reach our
goals. I wish to thank our many loyal shareholders and reiterate my
unwavering commitment to both restore and create shareholder
value.”
The Company will continue to update shareholders as additional
material event(s) occur.
Personal Bio, Mr. Anthony Amato - Age 56
Anthony Amato is a business leader and entrepreneurial thinker
with an intuitive ability to rapidly assess challenges and identify
growth opportunities. He quickly sees organizational vision and
understands goals, taking appropriate ownership and action required
to guide the team, achieving aggressive targets and performance
levels. He has outstanding interpersonal, business development,
team building and management skills. Anthony has hands-on executive
skills at engaging and influencing key stakeholders to not only
grow business but also to optimize profits.
Mr. Amato founded InQuest Science in March 2017 and then
acquired Bridge Associates International Pharmaceutical Consulting
in March 2020. He is the former Director of Sales for Mesa Labs in
Denver CO, a Nasdaq listed corporation that specializes in
providing quality control products and services to ensure the
safety and efficacy of equipment used in hospitals, pharmaceutical,
medical device manufacturers, blood banks, laboratories,
pharmacies, and industrial facilities.
In July of 1999, he founded Amega Scientific Corporation. He
grew the company from a start-up operation to a worldwide industry
leader. Anthony developed and managed a staff throughout North
America, establishing R&D, production, logistics,
administration and sales. Clients included pharmaceutical, biotech,
hospitals, government facilities, and research universities. Amega
Scientific was the leading innovator in the Environmental
Monitoring System industry. Amega Scientific was an ISO 17025
corporation instituting GxP requirements. Amega Scientific was
acquired by Mesa Labs (MLAB) in November 2013.
Mr. Amato graduated from Glassboro State College in New Jersey
in 1989, with a dual degree in business management and finance.
About BioSig Technologies, Inc. (NASDAQ: BSGM)
BioSig Technologies is a medical technology company focused on
deciphering the body’s electrical signals, starting with heart
rhythms. By leveraging a first of its kind combination of hardware
and software, we deliver unprecedented cardiac signal clarity,
ending the reliance on ‘mixed signals’ and ‘reading between the
lines.’ Our platform technology is addressing some of healthcare’s
biggest challenges—saving time, saving costs, and saving lives.
The Company’s product, the PURE EP™ Platform, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform highly targeted
cardiac ablation procedures with increased procedural efficiency
and efficacy.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of
future performance, are based on certain assumptions, and are
subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted
or quantified and consequently, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with (i) BioSig’s
ability to regain compliance with and meet the continued listing
requirements of the Nasdaq Capital Market to maintain listing of
its common stock; (ii) our cost reduction plan and associated
workforce reduction or other cost-saving measures not reaching the
targeted reduction of cash burn by 50%; (iii) the geographic,
social, and economic impact of pandemics or worldwide health issues
on BioSig’s ability to conduct its business and raise capital in
the future when needed; (iv) BioSig’s inability to manufacture its
products and product candidates on a commercial scale on its own,
or in collaboration with third parties; (v) difficulties in
obtaining financing on commercially reasonable terms; (vi) changes
in the size and nature of BioSig’s competition; (vii) loss of one
or more key executives or scientists; and (viii) difficulties in
securing regulatory approval to market BioSig’s products and
product candidates. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause BioSig’s actual results to differ from those contained in
forward-looking statements, see BioSig’s filings with the
Securities and Exchange Commission (“SEC”), including the section
titled “Risk Factors” in BioSig’s Annual Report on Form 10-K, filed
with the SEC on April 16, 2024. Investors and security holders are
urged to read these documents free of charge on the SEC's website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise, except as
required by law.
Todd Adler
BioSig Technologies, Inc.
Investor Relations
55 Greens Farms Rd
Westport, CT 06880
tadler@biosigtech.com
203-409-5444 ext. 104
Or
Anthony Amato, Chief Executive Officer
aamato@biosigtech.com
203-409-5444 ext. 102
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024